Aberdeen Group
BIO icon

Aberdeen Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aberdeen Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,233
Closed -$2.25M – 922
2024
Q2 		$2.25M Sell
8,233
-430
-5% -$125K ﹤0.01% 740
2024
Q1 		$3M Sell
8,663
-129
-1% -$42.4K 0.01% 740
2023
Q4 		$2.84M Buy
8,792
+3,588
+69% +$1.12M 0.01% 748
2023
Q3 		$1.87M Sell
5,204
-261
-5% -$101K ﹤0.01% 703
2023
Q2 		$2.07M Sell
5,465
-234
-4% -$95.2K ﹤0.01% 718
2023
Q1 		$2.73M Sell
5,699
-2,566
-31% -$1.2M 0.01% 685
2022
Q4 		$3.48M Buy
8,265
+3,085
+60% +$1.25M 0.01% 614
2022
Q3 		$2.16M Buy
5,180
+31
+0.6% +$15.5K 0.01% 697
2022
Q2 		$2.56M Sell
5,149
-186
-3% -$96.9K 0.01% 681
2022
Q1 		$3.06M Sell
5,335
-995
-16% -$600K 0.01% 676
2021
Q4 		$4.78M Sell
6,330
-744
-11% -$557K 0.01% 645
2021
Q3 		$5.3M Sell
7,074
-2,293
-24% -$1.72M 0.01% 643
2021
Q2 		$6.04M Sell
9,367
-180
-2% -$110K 0.01% 606
2021
Q1 		$5.45M Buy
9,547
+325
+4% +$192K 0.01% 629
2020
Q4 		$5.38M Buy
9,222
+2,578
+39% +$1.47M 0.01% 586
2020
Q3 		$3.42M Buy
6,644
+524
+9% +$265K 0.01% 629
2020
Q2 		$2.76M Buy
6,120
+4,809
+367% +$2.12M 0.01% 656
2020
Q1 		$460K Buy
1,311
+171
+15% +$62.9K ﹤0.01% 843
2019
Q4 		$422K Buy
+1,140
New +$402K ﹤0.01% 895

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aberdeen Group's BIO Position: Q3 2024 in Review

Aberdeen Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 8,233 shares — an estimated $2.25M sold.

Aberdeen Group first reported a position in BIO in Q4 2019 and held it in 19 quarters. The position peaked at $6.04M in Q2 2021. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Aberdeen Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 8,233 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $2.25M.
  • Aberdeen Group first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 19 quarters.
  • Aberdeen Group's Bio-Rad Laboratories Class A position peaked at $6.04M in Q2 2021.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.